- Home
- CRT vs VERU Comparison
CRT vs VERU Comparison
Compare CRT & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- VERU
- Stock Information
- Founded
- CRT 1991
- VERU 1971
- Country
- CRT United States
- VERU United States
- Employees
- CRT N/A
- VERU N/A
- Industry
- CRT Oil & Gas Production
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- VERU Health Care
- Exchange
- CRT Nasdaq
- VERU Nasdaq
- Market Cap
- CRT 65.1M
- VERU 54.6M
- IPO Year
- CRT 1992
- VERU 1990
- Fundamental
- Price
- CRT $7.70
- VERU $4.29
- Analyst Decision
- CRT
- VERU Strong Buy
- Analyst Count
- CRT 0
- VERU 3
- Target Price
- CRT N/A
- VERU $33.33
- AVG Volume (30 Days)
- CRT 25.2K
- VERU 158.4K
- Earning Date
- CRT 01-01-0001
- VERU 08-12-2025
- Dividend Yield
- CRT 9.63%
- VERU N/A
- EPS Growth
- CRT N/A
- VERU N/A
- EPS
- CRT 0.92
- VERU N/A
- Revenue
- CRT $6,559,820.00
- VERU $16,886,419.00
- Revenue This Year
- CRT N/A
- VERU N/A
- Revenue Next Year
- CRT N/A
- VERU N/A
- P/E Ratio
- CRT $8.33
- VERU N/A
- Revenue Growth
- CRT N/A
- VERU 337.24
- 52 Week Low
- CRT $7.14
- VERU $2.64
- 52 Week High
- CRT $13.31
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- CRT 42.69
- VERU 74.55
- Support Level
- CRT $7.38
- VERU $3.75
- Resistance Level
- CRT $7.75
- VERU $3.99
- Average True Range (ATR)
- CRT 0.21
- VERU 0.24
- MACD
- CRT 0.06
- VERU -0.01
- Stochastic Oscillator
- CRT 75.24
- VERU 94.34
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.